NBT Bank N.A. purchased a new position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,240 shares of the medical research company’s stock, valued at approximately $602,000.
Other hedge funds have also bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of IQVIA during the second quarter worth approximately $2,811,292,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of IQVIA by 9.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock worth $315,772,000 after acquiring an additional 134,997 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in IQVIA by 4.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock worth $282,657,000 after acquiring an additional 66,643 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of IQVIA during the second quarter valued at approximately $240,911,000. Finally, Bank of America Corp DE purchased a new position in IQVIA in the 2nd quarter worth about $235,551,000. 89.62% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on IQV. Barclays raised their target price on IQVIA from $275.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. BMO Capital Markets increased their price objective on shares of IQVIA from $270.00 to $305.00 in a research note on Monday, October 19th. UBS Group initiated coverage on shares of IQVIA in a report on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price objective on the stock. TD Cowen boosted their target price on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Finally, Robert W. Baird upped their target price on shares of IQVIA from $287.00 to $324.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $278.75.
View Our Latest Analysis on IQVIA
IQVIA Trading Up 0.4%
Shares of IQV opened at $279.47 on Friday. The stock has a market capitalization of $46.00 billion, a PE ratio of 34.67, a P/E/G ratio of 2.45 and a beta of 1.17. The company’s fifty day moving average is $263.98 and its 200 day moving average is $216.43. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $282.98.
IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter last year, the business earned $2.81 earnings per share. IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.54 earnings per share for the current fiscal year.
Insider Activity
In related news, insider Eric Sherbet sold 5,000 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. The trade was a 57.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is owned by insiders.
About IQVIA
IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.
Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.
Featured Articles
- Five stocks we like better than IQVIA
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
- Chefs’ Warehouse Has Rallied 76%—Can the Stock Keep Climbing?
- MarketBeat Week in Review – 10/19 – 10/23
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
